Introduction

Heat shock protein 90 (Hsp90) is a highly conserved molecular chaperone that plays an important role in protein regulation in cells. It accounts for nearly 1% of the total protein of the cell and is involved in the folding of many proteins, maintains their stability, protects from aggregation, and is a component of cellular machinery (1–3). Hsp90 was found to be overexpressed in a wide range of tumors, and thus it became a target of interest in oncology. Selectivity of natural and synthetic Hsp90 inhibitors toward cancer cells was demonstrated; thus, they are being developed as anticancer drugs (4–6). Currently, approximately 15 drug candidates are being tested as single agents or combined with other anticancer drugs in phase 1, 2, or 3 clinical trials.

Some of Hsp90 inhibitors bind to the N-terminal domain at the active site of ATP-binding pocket while others bind to the C-terminal domain. There are two groups of inhibitors binding at the N-terminal domain designed based on natural compounds: geldanamycin and radicicol. Both the compounds have been modified into new derivatives with desired efficiency and reduced toxicity (7, 8). Geldanamycin has been modified to 17-AAG and 17-DMAG, while various resorcinol-bearing compounds were designed based on radicicol. Here we describe the thermodynamics of their binding to Hsp90 by isothermal titration calorimetry (ITC) and thermal shift assay (TSA). These assays together with structural information of the Hsp90-inhibitor complex provide insight into the structure-activity relationship (SAR) of the compounds. The SAR helps in the process of rational drug design (9).

Hsp90 Structure

The molecular weight of Hsp90 is approximately 90 kDa, and it is found in all prokaryotic and eukaryotic cells. There are two highly homologous isoforms in human: α and β. Alpha isoform is prevalent (10), and there are no major known functional differences between the isoforms. Hsp90 homolog in yeast is named Hsc82 and also shares significant homology with human isoforms. Prokaryotic Hsp90 is called HtpG (for high temperature protein G), and it lacks the charged linker between the N-terminal and the middle domains (11). Plasmodium falciparum Hsp90 is 64% identical to its human analog (12). As shown in the sequence comparison of Hsp90 homologs in distant kingdoms (Fig. 1), Hsp90 is a highly conserved protein (13, 14).

The structure of yeast Hsc82 is shown in Fig. 2. The protein consists of three major domains: the amino terminal (N) domain (1–216 amino acids), the middle (M) domain (262–524 amino acids), and the carboxy terminal (C) domain (525–709 amino...
N-terminal domain (1–216 amino acids)

M-terminal domain (262–524 amino acids)

C-terminal domain (525–709 amino acids)

Fig. 1. Alignment of amino acid sequences

1, human Hsp90 alpha; 2, human Hsp90 beta; 3, Plasmodium falciparum Hsp90; 4, Saccharomyces cerevisiae Hsc82; and 5, Helicobacter felis HtpG. Amino acid residues with high consensus (90%) are shown in red, amino acids with 50% consensus are shown in blue. Different regions of the protein are boxed by different colors: ■, N-terminal domain; □, M-domain; and □, C-terminal domain.

acids) (3). There is a charged linker between N-terminal and middle domains, but so far it was not possible to obtain the crystal structure of this region, and thus its structure is unknown (15).

The function of Hsp90 has been studied and reviewed in a number of manuscripts (2, 3). ATPase activity is necessary for the chaperone cycle, and inhibitor binding in the N-terminal domain ATP-binding pocket blocks the activity of Hsp90 and formation of its complex. Inhibition leads to client protein degradation and cell death (16).

Fig. 2. The structure of full-length Hsc82 dimer (PDB ID: 2cg9)

One monomer is shown in dark green-red-dark blue and another in light green-pink-light blue. Green shows the position of the N-terminal domains. ATP is bound in the N-terminal domain and is shown in yellow.

Medicina (Kaunas) 2011;47(8)
**Inhibitors of Hsp90**

The majority of Hsp90 inhibitors bind to the N-terminal ATP pocket and block ATPase activity (Fig. 3). Hsp90 inhibition was thoroughly studied based on geldanamycin binding to Hsp90 and discussed in (17, 18). This natural compound from ansamycin family was found to be a strong inhibitor of chaperone in vitro and in vivo, but it demonstrated undesired liver toxicity (19) and could not be developed further as an anticancer agent. Later, some of its derivatives, namely 17-allylamino-17-demethoxygeldanamycin (17-AAG) and 17-(2-dimethylaminoethyl)amino-17-demethoxygeldanamycin (17-DMAG), have been developed and showed rather good antitumor activity (20). 17-AAG was the first Hsp90 inhibitor studied in clinical trials. Despite its high potency, 17-AAG showed poor solubility and stability and demonstrated moderate toxicity in several clinical trials (21). This compound attracted more attention after it was revealed as a useful agent for combined therapy since it enhanced efficacy of other chemotherapeutic agents (22).

Fig. 3. The chemical structures of selected Hsp90 inhibitors described in this review. Thermodynamics of binding of ICPD inhibitors based on resorcinol scaffold is described below.
Another natural product, radicicol, is a very strong Hsp90 inhibitor and competes with ATP binding in the N-terminal domain. Despite its high activity in vitro, radicicol lacks in vivo efficacy. However, its resorcinol-bearing derivatives possess good antitumor activity in animals (23).

Experience with the natural products encouraged scientists to seek for new synthetic Hsp90 inhibitors. Based on ATP structure, a group of purine derivatives has been designed (24, 25). One of them (PU3) demonstrated better solubility than clinical candidate 17-AAG but was not as potent. After some optimizations, better inhibitors have been found (26). Compound BIIB021 was identified to be a stronger inhibitor in vitro and in vivo as compared with 17-AAG (27) and is now being tested in phase 2 clinical trials.

Using structure-based design approach, diarylpyrazole derivatives have been identified as potent Hsp90 inhibitors (28). VER49009 was the most active, and its binding mode to the N-terminal domain was studied using x-ray crystallography. Water molecules, essential for binding, were identified, and the deeper understanding of binding features led to the identification of an Hsp90 inhibitor, NVP-AUY922, which was the second synthetic compound to enter clinical trials and demonstrate early success (29, 30).

Fragment-based drug discovery approach, focusing on physicochemical and pharmacokinetic properties, yielded the compound AT-13387. It showed not only good efficacy and selectivity, but also high solubility and metabolic stability; therefore, it was selected for clinical development (31).

Several additional groups of Hsp90 inhibitors have been discovered and successfully entered clinical trials. According to the US National Institutes of Health website (www.clinicaltrials.gov), at least 15 Hsp90 inhibitors as single agents or in combinations are being investigated in clinical trials (Table), and more than 40 clinical trials have been already completed (32). New inhibitors have been designed based on benzamide (33), 2-aminothieno[2,3-d]pyrimidine (34), and dihydroxyphenylisoindoline (35) scaffolds. There are at least several classes of compounds that have not been disclosed yet.

Most Hsp90 inhibitors are investigated as anticancer agents for a wide range of different types of tumors (36, 37). However, there are also data supporting their application for the treatment of neurodegenerative diseases, such as Alzheimer’s disease (38), Parkinson’s disease, multiple sclerosis, Huntington’s disease (39), rheumatoid arthritis (40), diabetes, ischemia (41), systemic lupus erythematosus (42), cystic fibrosis (43), fungal bacterial protozoan and viral infectious diseases (12, 44–46) and even are used as male contraceptives (47).

The most advanced drug candidates are 17-AAG that has already passed phase 3 clinical trials in combination with bortezomib in patients with relapsed-refractory multiple myeloma and STA-9090 that is currently being tested in phase 3 clinical trials in patients with advanced non–small lung cancer. Five compounds are being tested in phase 1 or 2 clinical trials and are promising leads in treating patients with Hsp90 inhibitors. However, during the last few years, some clinical trials with compounds XL888, IPI-493, and ABI010 have been terminated because of sponsor’s decision, discontinuation of program, or for example, due to the fact that drug exposure of retaspimycin HCl was found to be superior to IPI-493, and Infinity Pharmaceuticals, Inc., has decided to focus exclusively on retaspimycin.

| Inhibitor                  | Combined Drug                                                                 | Phase | Route       |
|---------------------------|------------------------------------------------------------------------------|-------|-------------|
| Tanespimycin (17-AAG)     | Alone or with bortezomib or gemcitabine hydrochloride                         | 1/2/3 | Intravenous |
| Retasapimycin (IPI-504)   | –                                                                             | 1/2   | Intravenous |
| Alvespimycin hydrochloride (17-DMAG) | Alone or with trastuzumab or paclitaxel                                         | 1     | Intravenous |
| NVP-AUY922                | Alone or combined with erlotinib hydrochloride, capецitabine, trastuzumab or cetuximab | 1/2   | Intravenous |
| HSP990                    | –                                                                             | 1     | Oral        |
| AT13387                   | Alone or with imatinib                                                        | 1/2   | Intravenous |
| BIIB021                   | –                                                                             | 1/2   | Oral        |
| BIIB028                   | –                                                                             | 1     | Oral        |
| Debio 0932                | –                                                                             | 1     | Oral        |
| DS-2248                   | –                                                                             | 1     | Oral        |
| KW-2478                   | Bortezomib                                                                   | 1/2   | Intravenous |
| MPC-3100                  | –                                                                             | 1     | Oral        |
| PU-H71                    | –                                                                             | 1     | Intravenous |
| SNX-5422 mesylate         | –                                                                             | 1     | Oral        |
| STA-9090                  | Alone or with docetaxel                                                       | 1/2/3 | Intravenous |

Medicina (Kaunas) 2011;47(8)
Thermodynamics of Hsp90 Ligand Binding

Detailed knowledge about structure-activity relationships could help in the development of new and more potent inhibitors (48). However, the thermodynamic characterization of ligand binding to Hsp90 chaperone is rather fragmented despite its importance. Here we describe some basics of protein–ligand binding thermodynamics.

Protein–ligand binding equilibrium is described by the Gibbs free energy of binding (ΔbG). More negative ΔbG indicates a stronger binding reaction. However, several thermodynamic parameters that contribute to the ΔbG can be correlated with the structural features of the protein–ligand complex easier than the ΔbG itself. The most important parameters are the enthalpy (ΔbH) and the entropy (ΔbS) of binding:

$$\Delta_b G = \Delta_b H - T \Delta_b S$$

Both the enthalpy and entropy are the first temperature derivatives (T-derivatives) of the Gibbs free energy:

$$\left( \frac{\partial \Delta_b G}{\partial T} \right)_P = -\Delta_b S$$

$$\frac{\partial \ln K_b}{\partial T} = \frac{\Delta_b H}{R T^2}$$

The second T-derivative of the ΔbG is the heat capacity of binding (ΔbCp). Subscript P indicates constant pressure.

$$\Delta_b C_p = \left( \frac{\partial \Delta_b H}{\partial T} \right)_P$$

A number of various methods may be used for the measurement of the Gibbs free energy of ligand binding (49). Here we concentrate on two methods, ITC and TSA, also known as differential scanning fluorimetry (50). Both the methods have been previously reviewed, but ITC is used more widely (51, 52) than TSA despite its some important advantages (53–56).

ITC directly measures the heat evolved or absorbed during the binding reaction. This method is the most robust and accurate way of measuring the ΔbH. However, the ITC has a number of disadvantages. Most importantly, the binding constant should be in a rather narrow range to satisfy the requirement that coefficient c would be between about 5 and 500. The c is calculated as follows:

$$c = n M_c K_b$$

where n is the binding stoichiometry, M is the protein molar concentration, and Kb is the binding constant defined for the reaction of $M + L \leftrightarrow ML$ as:

$$K_b = \frac{[ML]}{[L][M]}$$

Kb is related to the Gibbs free energy:

$$\Delta G = -RT \ln K_b$$

In practice, ITC is useful for Kbs in the range of 105 to 109 M⁻¹. Another disadvantage of ITC is that it requires rather a large amount of protein (usually more than 0.1 mg) and ligand. These disadvantages can be quite easily approached using TSA. This method is based on the observation that specifically binding ligands stabilize (sometimes destabilize) the protein. TSA requires only several micrograms of protein. Furthermore, there is no upper limit of the Kbs to be determined. The only limit is the temperature of water boiling. Therefore, extremely tight reactions as radicicol binding to Hsp90 can be studied by TSA. However, TSA does not determine ΔbH, ΔbS, and ΔbCp as distinct from ITC. Therefore, both ITC and TSA could be used together for an increased precision of the measurements (56).

Fig. 4 shows a typical ITC binding curve of the Hsp90-ligand system. Due the linked protonation, it is important to dissect protonation thermodynamics from binding thermodynamics in order to determine the intrinsic thermodynamics of binding. For example, the enthalpy of TRIS buffer protonation is so large (about ~44 kJ/mol) that it would significantly alter any binding enthalpies. Therefore, a series of experiments in various buffers are necessary (55).

The binding of measurement by TSA is shown in Fig. 5. Panel A shows typical raw protein melting curves at various ICPD47 concentrations added. Fig. 5B shows the $T_m$ shift curves for 17-AAG and ICPD47 as a function of inhibitor concentration. ICPD47, a more potent binder than 17-AAG, shifts the temperature by up to 12°C, while 17-AAG, a weaker binder, shifts the temperature by up to 4°C.

True intrinsic binding thermodynamic parameters could be obtained only after the detailed proton linkage and temperature analysis as previously described (55). This analysis and the crystallographic structure of Hsp90-inhibitor complex are not the subject of this review but are in preparation for publishing (unpublished data). The intrinsic dissociation constants were 1.1 nM for ICPD47 and 2.0 nM for ICPD62. However, the ICPD60 binding could not be detected, thus its Kd is weaker than 200 μM.
The Cl atom between the OH groups interferes with binding.

**In Vitro Anticancer Activity of Hsp90 Inhibitors**

After the determination of intrinsic thermodynamic parameters of binding and x-ray crystallographic structures of the most potent inhibitors, it is necessary to test the compounds against several cancer cell lines. The effect of ICPD compound on cancer cells was tested by determining cell growth, death, and survival as a function of compound concentration for two selected cancer cell lines – U2OS (osteosarcoma) and HeLa (cervical carcinoma) – using tetrazolium/formazan assay (Fig. 6) (57). ICPD60 was relatively weak and exhibited off-target activity against the cancer cell lines. This property correlates well with its weak binding to Hsp90. Other compounds exhibited the average potency of cancer cell growth inhibition. The compound series has potential to become candidates for therapeutic anticancer treatment.

**Concluding Remarks**

Hsp90 is a prominent anticancer target. The ICPD series of compounds are highly potent inhibitors of Hsp90 (single digit nanomolar $K_d$). Biothermodynamic methods – isothermal titration calorimetry and thermal shift assay – are useful in the
characterization of compound binding efficiency to the target.

Acknowledgments
This research was funded by a grant (No. LIG-16/2010) from the Research Council of Lithuania. Vilma Petrikaitė thanks the Lithuanian Science Council for the fellowship obtained from the project “Postdoctoral Fellowship Implementation in Lithuania” funded by the European Union Structural Funds.

Statement of Conflict of Interest
The authors state no conflict of interest.

Natūralių ir sintetinių slopiklių jungimasis su žmogaus baltymu Hsp90 ir jų pritaikymas klinikuje

Vilma Petrikaitė, Daumantas Matulis
Vilniaus universiteto Biotechnologijos institutas

Raktažodžiai: Hsp90 slopikliai, priešvėžinis aktyvumas, izoterminio titravimo kalorimetrija, šiluminio poslinkio metodas, ThermoFluor®

Santrauka. Straipsnyje pateikiamas Hsp90 slopiklių kūrimo apžvalga. Hsp90 yra šiluminio šoko baltymas, kurio sanykinis molekulinis svoris yra apie 90 kDa. Hsp90 yra laikomas tinkamu priešvėžinių vaistų ir šiluminio poslinkio metodais. Taikant šiuos metodus, galima ištirti jungimosi reakcijų energetiką ir nustatyti tokius biofizinius parametrus, kaip entalpiją, entropiją, šiluminę talpą, laisvąją Gibso energiją. Išsamios informacijos apie jungimosi energetiką suteikia daugiau informacijos apie struktūros ir aktyvumo ryšį, aktyvesnių ir jų pritaikymo klinikiniuose tyrimuose.

Taip pat apžvelgiami biofiziniai metodai, naudojami kuriant Hsp90 slopiklius. Sukurtų junginių lyde-rių jungimasis su įvairiais Hsp90 konstruktais gali būti matuojamas izoterminio titravimo kalorimetrijoje ir šiluminio poslinkio metodais. Taikant šiuos metodus, galima ištirti jungimosi reakcijų energetiką ir nustatyti tokius biofizinius parametrus, kaip entalpiją, entropiją, šiluminę talpą, laisvąją Gibso energiją. Išsamios žinios apie jungimosi energetiką suteikia daugiau informacijos apie struktūros ir aktyvumo ryšį, aktyvesnių slopiklių kūrimą. Vėliau tiriamos aktyvesnųjų spinduliuotų vėžių ląstelių augimą.

References
1. Welch WJ, Feramisco JR. Purification of the major mammalian heat shock proteins. J Biol Chem 1982;257(14949–59.
2. Pearl LH, Prodomou C. Structure and mechanism of the Hsp90 molecular chaperone machinery. Annu Rev Biochem 2006;75:271–94.
3. Waddinger SK, Richter K, Buchner J. The Hsp90 chaperone machinery. J Biol Chem 2008;283:18473–7.
4. Taldone T, Gazman A, Maharaj R, Chiosis G. Targeting Hsp90: small-molecule inhibitors and their clinical development. Curr Opin Pharmacol 2010;9:1386–418.
5. Biamonte MA, Van de Water R, Arndt JW, Scannevin RH, Perret D, Lee W. Heat shock protein 90: inhibitors in clinical trials. J Med Chem 2010;53:3–17.
6. Porter JR, Ge J, Lee J, Normant E, West K. Ansamycin inhibitors of Hsp90: nature’s prototype for anti-chaperone therapy. Curr Topics Med Chem 2009;9:1386–418.
7. Sharp SY, Boxall K, Rowlands M, Prodomou C, Roe SM, Maloney A, et al. In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors. Cancer Res 2007;67(5):2206–16.
8. Taldone T, Sun W, Chiosis G. Discovery and development of heat shock protein 90 inhibitors. Bioorg Med Chem 2009;17(6):2225–35.
9. Ladbury JE, Klebe G, Freire E. Adding calorimetric data to decision making in lead discovery: a hot tip. Nat Rev Drug Discov 2010;9(1):23–7.
10. Hickey E, Brandon SE, Smale G, Lloyd D, Weber LA. Sequence and regulation of a gene encoding a human 89-kilodalton heat shock protein. Mol Cell Biol 1989;9(6):2615–26.
11. Buchner J. Bacterial Hsp90 – desperately seeking client. Mol Microbiol 2010;76(3):540–4.
12. Acharya P, Kumar R, Tatu U. Chaperoning a cellular upheaval in malaria: heat shock protein complexes in Plasmodium falciparum. Mol Biochem Parasitol 2007;153:85–94.
13. Rutherford SL, Lindquist S. Hsp90 as a capacitor for morphological evolution. Nature 1998;396(6709):336–42.
14. Chen B, Zhong D, Monteiro A. Comparative genomics and evolution of the HSP90 family of genes across all kingdoms of organisms. BMC Genomics 2006;7:156.
15. Ali MM, Roe SM, Vaughn CK, Meyer P, Panareotou B, Piper PW, et al. Crystal structure of an Hsp90-nucleotide-p23/sba1 closed chaperone complex. Nature 2006;440(7087):1013–7.
16. Solit DB, Chiosis G. Development and application of Hsp90 inhibitors. Drug Discov Today 2008;13:38–43.
17. Whitesell L, Minnaugh EG, De Costa B, Myers CE, Neckers LM. Inhibition of heat shock protein HSP90-pp60v-src heteroprotein complex formation by benzoquinone ansamycins: essential role for stress proteins in oncogenic transformation. PNAS 1994;91(18):8324–8.
18. Fukuyo Y, Hunt CR, Horikoshi N. Geldanamycin and its anti-cancer activities. Cancer Lett 2010;290(1):24–35.
19. Supko JG, Hickman RL, Grever MR, Malspeis L. Preclinical pharmacologic evaluation of geldanamycin as an antitumor agent. Cancer Chemother Pharmacol 1995;35:305–15.
20. Kamal A, Thao L, Sensintaffar J, Zhang L, Boehm MF, Fritz LC, et al. A high-affinity conformation of Hsp90 confers tumour selectivity on Hsp90 inhibitors. Nature 2003;425(6956):407–10.
21. Ronnen EA, Kondagunta GV, Ishill N, Sweeney SM, Deluca JK, Schwartz L, et al. Phase II trial of 17-(allylamino)-17-demethoxygeldanamycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a randomized, multicenter, phase II trial. J Clin Oncol 2008;26(6):906–12.
phase I dose-escalation study. J Clin Oncol 2007;25:5410-7.
23. Soga S, Shiotzu Y, Akinaga S, Sharma SV. Development of radicical analogues. Curr Cancer Drug Targets 2003;3:359-69.
24. Chiosis G, Lucas B, Shilt A, Huezlo H, Rosen N. Development of a purine-scaffold novel class of Hsp90 binders that inhibit the proliferation of cancer cells and induce the degradation of HER2 tyrosine kinase. Bioorg Med Chem 2002;10(11):3555-64.
25. Chiosis G, Timaui MN, Lucas B, Munster PN, Zheng FF, Sepp-Lorenzino L, et al. A small-molecule, designed to bind to the adenine nucleotide pocket of Hsp90 causes HER2 degradation and the growth arrest and differentiation of breast cancer cells. Chem Biol 2001;8(3):289-99.
26. Taldone T, Chiosis G. Purine-scaffold Hsp90 inhibitors. Curr Top Med Chem 2008;8(15):1346-46.
27. Lundgren K, Zhang H, Brekker J, Huser N, Powell RE, Timpile N, et al. BIBO212, an orally available, fully synthetic small-molecule inhibitor of the heat shock protein Hsp90. Mol Cancer Ther 2009;8(8):2121-9.
28. Cheung KM, Matthews TP, James K, Rowlands MG, Boxall KJ, Sharp SY, et al. The identification, synthesis, protein crystal structure and in vitro biochemical evaluation of a new 3,4-diarylpyrazole class of Hsp90 inhibitors. Bioorg Med Chem 2009;17(15):3338-43.
29. Brough PA, Aherne W, Barril X, Borgognoni J, Boxall KJ, Cansfield JE, et al. 4,5-diarylisoazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem 2008;51(2):196-218.
30. Gaspar N, Sharp SY, Eccles SA, Goos S, Popov S, Jones C, et al. Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma. Mol Cancer Ther 2010;9(5):1219-33.
31. Woodhead AJ, Angove H, Marr G, Chersari G, Congreve MC, Coyle JE, et al. Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperezin-1-ylmethyl)-1,3-dihydroisindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. J Med Chem 2010;53(16):5956-69.
32. Kuehn TC, Alcorn MA, Lee S, Lee MJ, Giaccone G, Neckers L, et al. Update on Hsp90 inhibitors in clinical trial. Curr Topics Med Chem 2009;9:1479-92.
33. Huang KH, Veal JM, Fadden RP, Rice JW, Eaves J, Strachan JP, et al. Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. J Med Chem 2009;52(14):4288-305.
34. Brough PA, Barril X, Borgognoni J, Boxall KJ, Cansfield JE, et al. 4,5-diarylisoazole Hsp90 chaperone inhibitors: potential therapeutic agents for the treatment of cancer. J Med Chem 2008;51(2):196-218.
35. Gaspar N, Sharp SY, Eccles SA, Goos S, Popov S, Jones C, et al. Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma. Mol Cancer Ther 2010;9(5):1219-33.
36. Woodhead AJ, Angove H, Marr G, Chersari G, Congreve MC, Coyle JE, et al. Discovery of (2,4-dihydroxy-5-isopropylphenyl)-[5-(4-methylpiperezin-1-ylmethyl)-1,3-dihydroisindol-2-yl]methanone (AT13387), a novel inhibitor of the molecular chaperone Hsp90 by fragment based drug design. J Med Chem 2010;53(16):5956-69.
37. Kuehn TC, Alcorn MA, Lee S, Lee MJ, Giaccone G, Neckers L, et al. Update on Hsp90 inhibitors in clinical trial. Curr Topics Med Chem 2009;9:1479-92.
38. Huang KH, Veal JM, Fadden RP, Rice JW, Eaves J, Strachan JP, et al. Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. J Med Chem 2009;52(14):4288-305.
39. Brough PA, Barril X, Borgognoni J, Chene P, Davies NG, Davis B, et al. Combining hit identification strategies: fragment-based and in silico approaches to orally active 2-aminothieno[2,3-d]pyrimidine inhibitors of the Hsp90 molecular chaperone. J Med Chem 2009;52(15):4749-809.
40. Kung PP, Huang B, Zhang G, Zhou JZ, Wang J, Digits JA, et al. Dihydroxyphenylisodindole amides as orally bioavailable inhibitors of the heat shock protein 90 (Hsp90) molecular chaperone. J Med Chem 2010;53(1):499-503.
41. Ortiz AG, Salcedo JM. Heat shock proteins as targets in oncology. Clin Transl Oncol 2010;12(3):166-73.
42. Barta TE, et al. Small molecule inhibitors of Hsp90 potentially affect inflammatory disease pathways and exhibit activity in models of rheumatoid arthritis. Arthritis Rheum 2008;58:3765-75.
43. Stephanou A, Latchman DS, Isenberg DA. The regulation of heat shock proteins and their role in systemic lupus erythematosus. Semin Arthritis Rheum 1998;28:155-62.
44. Jouret F, Devoust O, CFT and defective endocytosis: new insights in the renal phenotype of cystic fibrosis. Pflugers Arch 2009;457:1227-36.
45. Cowen LE, Steinback WJ. Stress, drugs, and evolution: the role of cellular signaling in fungal drug resistance. Eukaryot Cell 2008;7:747-64.
46. Neckers L, Tatu U. Molecular chaperones in pathogen virulence: emerging new targets for therapy. Cell Host Microbe 2008;4:519-27.
47. Shonhai A. Plasmoidal heat shock proteins: targets for chemotherapy. FEBS Immunol Med Microbiol 2010;58(1):61-74.
48. Bash J, Chakrarsal R, Jakkaraj SR, Hughes J, Smith SK, Hornibaker K, et al. Gamendazole, an orally active indazole carboxylic acid male contraceptive agent, targets Hsp90BETA (Hsp90BETA) and EEF1A1 (eEf1A), and stimulates mRNA transcription in rat sertoli cells. Biol Reprod 2008;78:1139-52.
49. Velázquez Campoy A, Freire E. ITC in the post-genomic era...? Priceless. Biophys Chem 2005;115:115-24.
50. Soti C, Nagyi EM, Kaufman GK, Urbach AR, Gitlin I, Gudiksen KL, Weibel DB, et al. Carbonic anhydrase as a model for biophysical and physical-organic studies of proteins and protein-ligand binding. Chem Rev 2008;108(3):946-1051.
51. Niesen FH, Berglund H, Vedadi M. The use of differential scanning fluorimetry to detect ligand interactions that promote protein stability. Nat Protoc 2007;2:2212-21.
52. Ladbury JE. Application of isothermal titration calorimetry in the biological sciences: things are heating up! Biotechniques 2004;37(6):885-7.
53. Freyer MW, Lewis EA. Isothermal titration calorimetry: experimental design, data analysis, and probing macromolecule/ligand binding and kinetic interactions. Methods Cell Biol 2008;84:79-115.
54. Cimperman P, Matulis D. Protein thermal denaturation measurements via a fluorescent dye. In: Podjarny A, Dejaegere A, Kieffer B, editors. Bioophysical approaches determining ligand binding to biomolecular targets. 1st ed. Cambridge: RSC; 2010. p. 247-77.
55. Zubriene A, Matulieniene J, Baranauskieniene J, Iachno J, Torresan J, Michailovienė V, et al. Measurement of nanomolar dissociation constants by titration calorimetry and thermal shift assay – radioligand binding to Hsp90 and ethoxzolamide binding to CAII. Int J Mol Sci 2009;10(6):2662-80.
56. Zubriene A, Gurskova M, Michailovienė J, Chaleckis R, Michailovienė V, Voroncova A, et al. Thermodynamics of radioligand binding to human Hsp90 alpha and beta isoforms. Biophys Chem 2010;152:153-63.
57. Matulis D, Krant JK, Salemmre FR, Todd MJ. Thermodynamic stability of carbonic anhydrase: measurements of binding affinity and stoichiometry using Thermofluor. Biochemistry 2005;44(13):5258-66.
58. Cikotiene I, Kuzlauskas E, Matulieniene J, Michailovienė V, Torresan J, Iachno J, et al. 3-Aryl-4-([4-substituted-2,4-di hydroxophenyl]-1,2,3-thiazololes as inhibitors of Hsp90 chaperone. Bioorg Med Chem Let 2009;19:1089-92.